These data support the anti-apoptotic role of aberrantly expressed IRX2 and IRX3 in BCP-ALL and highlight these IRX oncogenes as novel therapeutic targets in combination with conventional chemotherapeutic drugs. The gene discussed is IRX3; the disease is acute lymphoblastic leukemia.